5035p 85.0 1.7%
Last Trade - 26/02/21
| Market Cap | £3.29bn |
| Enterprise Value | £3.39bn |
| Revenue | £551.4m |
| Position in Universe | 229th / 1807 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 398.5 | 388.3 | 459.1 | 470.3 | 488.5 | 551.4 | 575.9 | 626.7 | +6.7% | ||
| -15.0 | +26.0 | +7.9 | -9.8 | -3.1 | +41.9 | +41.5 | +7.02 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company's segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe. The Genus ABS segment is engaged in bovine sales business, excluding Asia, and serves dairy and beef customers in North America, Latin America and Europe. The Genus Asia segment is engaged in porcine and bovine business in Asia, and serves porcine, dairy and beef customers in Asian markets. In the porcine market, it sells boars and sows. In the dairy and beef markets, its primary product is bull semen. The Company offers embryos through its subsidiary, In Vitro Brasil S.A. Its porcine business has a network of over 600 breeding herds in approximately 40 countries.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | September 26, 1994 |
| Public Since | July 6, 2000 |
| No. of Shareholders: | n/a |
| No. of Employees: | 2,969 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE All Share , FTSE All-share - Health Care Price Return Gbp End Of Day, FTSE All-share - Pharmaceuticals & Biotechnology Price Return Gbp End Of Day, FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology , FTSE Techmark Focus , FTSE Techmark All Share , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 65,301,337 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Matrix House Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom |
| Web | https://www.genusplc.com |
| Phone | +44 1256 347100 |
| Contact | Charles Ryland (IR Contact Officer) |
| Auditors | Deloitte LLP |
As of 26/02/21, shares in Genus are trading at 5035p, giving the company a market capitalisation of £3.29bn. This share price information is delayed by 15 minutes.
Shares in Genus are currently trading at 5035p and the price has moved by 59.44% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genus price has moved by 54.59% over the past year.
Of the analysts with advisory recommendations for Genus, there are there are currently 5 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Genus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Genus is scheduled to issue upcoming financial results on the following dates:
The Genus dividend yield is 0.58% based on the trailing twelve month period.
Last year, Genus paid a total dividend of 0.29, and it currently has a trailing dividend yield of 0.58%. Looking ahead, shares in Genus are due to go ex-dividend on 2021-03-04 and the next dividend pay date is 2021-04-01.
Genus are due to go ex-dividend on 2021-03-04 and the next dividend pay date is 2021-04-01. The historic dividend yield on Genus shares is currently 0.58%.
To buy shares in Genus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Genus are currently trading at 5035p, giving the company a market capitalisation of £3.29bn.
Here are the trading details for Genus:
Based on an overall assessment of its quality, value and momentum, Genus is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Genus are currently priced at 5035p. At that level they are trading at 0.08% premium to the analyst consensus target price of 5,030.98.
Analysts covering Genus currently have a consensus Earnings Per Share (EPS) forecast of 1.02195 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genus. Over the past six months, the relative strength of its shares against the market has been 29.77%. At the current price of 5035p, shares in Genus are trading at 26.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genus PE ratio based on its reported earnings over the past 12 months is 69.72. The shares are currently trading at 5035p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genus's management team is headed by:
Here are the top five shareholders of Genus based on the size of their shareholding:
